

Formulation 1 - Bimatoprost 20%, R203s 45%, RG752s 20%, R202H 10%, PEG-3350 5%
Formulation 2 - Bimatoprost 20%, R203s 20%, RG752s 40%, R202H 15%, PEG-3350 5%
Average Total Release (%)
0
10
20
30
40
50
60
70
80
90
100
0
20
40
60
80
100
Time (Days)

FIG. 1



Formulation 1
Formulation 2
Diameter (µm)
2000
1800
1600
1400
1200
1000
800
600
400
200
0
0
20
40
60
80
100
120
140
160
180
200
Time (days)

FIG. 2A





Formulation 1
Formulation 2
Length (µm)
2400
2200
2000
1800
1600
1400
1200
1000
800
600
400
200
0
0
20
40
60
80
100
120
140
160
180
200
Time (days)

FIG. 2B




Swelling behavior for Bimatoprost Implant Formulations 1 and 2.

FIG. 3



Between group comparison of bimatoprost formulations 2, 6, 7 and 8 on IOP reduction in normal Beagle dogs using ANOVA; t = $p<0.05$. There was a statistically significant difference at 4 months in favor of formulation 8.

FIG. 4



Between group comparison of bimatoprost formulations 2, 6, 7 and 8 on pupil size reduction in normal Beagle dogs using ANOVA; t = $p<0.05$. There was a statistically significant difference at 0.25 and 0.5 months in favor of formulation 2.

FIG. 5

Mean Corneal Endothelial Cell Density in Beagle dogs through Week 26 of the Dosing Phase (combined sexes) following administration of a bimatoprost-containing implant to the anterior chamber of the eye. The implants comprised Formulation 1 and were prepared by an extrusion process. Treated dogs received one implant in the right eye.




FIG. 6




FIG. 7